Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) Sees Significant Growth in Short Interest

Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 26,200 shares, an increase of 37.2% from the February 13th total of 19,100 shares. Based on an average daily trading volume, of 53,400 shares, the days-to-cover ratio is presently 0.5 days.

Analyst Upgrades and Downgrades

Separately, Raymond James reiterated a “strong-buy” rating on shares of Medexus Pharmaceuticals in a research note on Monday, February 3rd.

Medexus Pharmaceuticals Trading Down 1.1 %

MEDXF traded down $0.02 on Friday, reaching $1.77. The company’s stock had a trading volume of 2,964 shares, compared to its average volume of 39,801. Medexus Pharmaceuticals has a 1 year low of $1.08 and a 1 year high of $3.88. The business’s 50 day moving average is $2.39 and its 200 day moving average is $2.06.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.